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We read with interest the paper by Requena-Méndez and col-leagues, who aimed to evaluate plasma concentrations of
isoniazid administered daily and twice weekly (1). The sampling
strategy to assess the area under the concentration-time curve
(AUC) consisted of obtaining two plasma samples at 2 and 6 h (C2
and C6, respectively) after intake of the drugs. In addition, the
maximum concentration of the drug in serum (Cmax) was defined
as the higher of either the C2 or the C6 concentration. They con-
cluded that low isoniazid exposure (the AUC from 0 to 6 h) or a
low Cmax was not associated with poorer clinical outcomes.
The authors summarized several limitations of their study. It is
most likely that the design of their pharmacokinetic study (i.e., C2
and C6 monitoring) explains why they failed to find such an asso-
ciation. They chose C2 and C6 monitoring because of logistical
reasons. Although this approach has been used frequently in the
past, this sampling strategy is suited neither for capturing theCmax
nor for accurately predicting the AUC of isoniazid. Earlier, Prahl
and colleagues showed that currently used target values for C2 are
not predictive of treatment efficacy and need to be redefined (2).
Due to the large pharmacokinetic variability of isoniazid, the true
Cmax will be captured only by intensive pharmacokinetic sampling
(3). In addition, estimation of the isoniazid AUC using two sam-
ples (C2 and C6) does not qualify to be placed among the best-
performing optimal sampling strategies for isoniazid (4). Obtain-
ing a full pharmacokinetic curve and using a validated limited
sampling strategy are the only two strategies of accurately predict-
ing the AUC. A more practical approach would include a third
sample at 4 h after drug intake (4). To overcome practical compli-
cations like sample stability, dried blood spot monitoring can be
helpful (5).
Requena-Mendez et al. suggested that weight-based twice-
weekly dosing is still a suitable alternative. We argue that their
study was not designed and lacked the power to relate this strategy
to treatment outcome. Conclusions on treatment outcome may
be further complicated by the fact that data regarding drug sus-
ceptibility were not available (1, 6). The earlier meta-analysis on
this subject showed that microbiological failure was more fre-
quent with the intermittent dosing schedules (7). Indeed, inter-
mittent dosing should no longer be recommended (8).
Only a well-designed sampling schedule and information on
drug intake and drug susceptibility in combination with long-
term follow-up will provide relevant data that may help to opti-
mize tuberculosis (TB) treatment.
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